by Annie De Groot | Oct 4, 2013 | News
Dr. Alan Rothman of iCubed discusses two large grants, totaling $21.4 million dollars for The University of Rhode Island. He also comments on the current status of the government and the effects on academic groups obtaining grants. (interview starts at 1:15) Read the...
by Annie De Groot | Sep 25, 2013 | News
https://convergenceri.com/ EpiVax commits resources to bring its Tregitope platform to clinic A pioneering firm in immunogenicity comes of age PHOTO BY SCOTT KINGSLEY Dr. Anne S. De Groot, CEO of EpiVax, Inc., is one of the original biotech pioneers in Rhode Island....
by Annie De Groot | May 20, 2013 | News
LIFE SCIENCES Vaccine development for H7N9 flu moving forward By Richard Asinof Contributing Writer Twitter: @RichardAsinof Posted 5/20/13 PROVIDENCE – It has been a very busy month and half for Dr. Anne S. De Groot and her team at EpiVax, a bioscience firm based in...
by Annie De Groot | May 11, 2013 | Thinking Out Loud -Blog
Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design Volume 9, Issue 5 May 2013 Keywords: Emerging Infectious Diseases, H7N9, Immunoinformatics, Influenza, T Cell Epitope, Vaccine, Vaccine Design Authors: Anne S. De...
by Annie De Groot | Apr 16, 2013 | News, Thinking Out Loud -Blog
An Update on EpiVax’ H7N9 “FastVax” Progress EpiVax scientists are currently in discussions with groups in China, Canada and the US about producing a vaccine. Here we highlight a few key points about the current progress of EpiVax’ FastVax...
